Eli Lilly and (NYSE:LLY) was upgraded by equities researchers at Argus from a “hold” rating to a “buy” rating in a report released on Friday, The Fly reports.
Other research analysts also recently issued research reports about the stock. BMO Capital Markets set a $73.00 price target on shares of Eli Lilly and and gave the stock a “sell” rating in a research report on Tuesday, December 5th. Leerink Swann upped their price target on shares of Eli Lilly and from $92.00 to $93.00 and gave the stock a “market perform” rating in a research report on Monday, October 23rd. Jefferies Group reiterated a “buy” rating and set a $89.00 price target on shares of Eli Lilly and in a research report on Monday, September 11th. Piper Jaffray Companies reiterated an “overweight” rating and set a $105.00 price target (up previously from $103.00) on shares of Eli Lilly and in a research report on Friday, September 8th. Finally, Credit Suisse Group reiterated a “hold” rating on shares of Eli Lilly and in a research report on Wednesday, December 13th. Three investment analysts have rated the stock with a sell rating, six have issued a hold rating and ten have assigned a buy rating to the company. Eli Lilly and presently has an average rating of “Hold” and a consensus price target of $90.25.
Shares of Eli Lilly and (LLY) opened at $85.52 on Friday. Eli Lilly and has a 52 week low of $74.00 and a 52 week high of $89.09. The company has a quick ratio of 1.03, a current ratio of 1.38 and a debt-to-equity ratio of 0.66. The company has a market cap of $93,747.23, a price-to-earnings ratio of 40.53, a PEG ratio of 1.60 and a beta of 0.35.
In other Eli Lilly and news, major shareholder Lilly Endowment Inc sold 200,000 shares of the company’s stock in a transaction dated Wednesday, December 13th. The shares were sold at an average price of $88.20, for a total transaction of $17,640,000.00. Following the transaction, the insider now directly owns 123,084,104 shares in the company, valued at approximately $10,856,017,972.80. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, SVP Jeffrey N. Simmons sold 12,500 shares of the company’s stock in a transaction dated Monday, December 11th. The shares were sold at an average price of $86.46, for a total transaction of $1,080,750.00. Following the transaction, the senior vice president now owns 124,522 shares in the company, valued at $10,766,172.12. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 251,088 shares of company stock worth $22,041,236. Corporate insiders own 0.20% of the company’s stock.
Several hedge funds have recently made changes to their positions in LLY. Kovitz Investment Group Partners LLC increased its stake in shares of Eli Lilly and by 2.1% in the 1st quarter. Kovitz Investment Group Partners LLC now owns 7,450 shares of the company’s stock valued at $627,000 after acquiring an additional 151 shares during the last quarter. OLD Mutual Customised Solutions Proprietary Ltd. increased its stake in shares of Eli Lilly and by 18.2% in the 1st quarter. OLD Mutual Customised Solutions Proprietary Ltd. now owns 15,482 shares of the company’s stock valued at $1,302,000 after acquiring an additional 2,382 shares during the last quarter. First Financial Equity Corporation bought a new stake in shares of Eli Lilly and in the 1st quarter valued at about $252,000. Janus Capital Management LLC increased its stake in shares of Eli Lilly and by 2.8% in the 1st quarter. Janus Capital Management LLC now owns 8,723,692 shares of the company’s stock valued at $733,731,000 after acquiring an additional 237,619 shares during the last quarter. Finally, Salem Investment Counselors Inc. increased its stake in shares of Eli Lilly and by 23.3% in the 1st quarter. Salem Investment Counselors Inc. now owns 35,800 shares of the company’s stock valued at $3,015,000 after acquiring an additional 6,754 shares during the last quarter. 76.30% of the stock is owned by institutional investors.
ILLEGAL ACTIVITY NOTICE: This piece of content was first reported by American Banking and Market News and is owned by of American Banking and Market News. If you are reading this piece of content on another publication, it was copied illegally and reposted in violation of U.S. and international trademark & copyright laws. The correct version of this piece of content can be accessed at https://www.americanbankingnews.com/2018/01/05/eli-lilly-and-lly-raised-to-buy-at-argus.html.
About Eli Lilly and
Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.
